#UC-MSCs
LightNews LightNews
shihcheng.bsky.social
18 patients with ischemic stroke received 50, 100, or 200M UC-MSCs in a phase 1 trial. Promising results from NIHSS scores (6-20, median 9). PMID:42208543, Cell Rep Med 2026 https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00253-3?rss=yes&utm_source=dlvr.it&utm_medium=twitter #RNA 🧪
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00253-3?rss=yes&utm_source=dlvr.it&utm_medium=twitter
No description available
www.cell.com
July 2, 2026 at 12:00 AM
bioinformant.bsky.social
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance - bioinformant.com/porton-advan...
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance | BioInformant
CRANBURY, N.J. and SUZHOU, China, July 8, 2026 — Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has bee...
bioinformant.com
July 15, 2026 at 12:52 AM
ppimentel-coelho.bsky.social
Intravenous human umbilical cord-derived mesenchymal stem cell transplantation for ischemic stroke (MERIT): A phase 1 trial

Lili Cui et al. 🧪

@cp-cellrepmed.bsky.social

www.sciencedirect.com/science/arti...
Intravenous human umbilical cord-derived mesenchymal stem cell transplantation for ischemic stroke (MERIT): A phase 1 trial
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) hold promise as a potential therapy for ischemic stroke, but the optimal transplantation strat…
www.sciencedirect.com
June 5, 2026 at 12:33 PM
walknews.bsky.social
ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立 | ヒューマンライフコード株式会社のプレスリリース

https://www.walknews.com/1373244/

世界に先駆けて臍帯由来間葉系間質細胞（以下「UC-MSCs」）を再生医療等製品としての実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田雅充、東京都中央区、以下「当社」）は、アラブ首長国連邦（UAE [...]
ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立 | ヒューマンライフコード株式会社のプレスリリース - WALK NEWS
世界に先駆けて臍帯由来間葉系間質細胞（以下「UC-MSCs」）を再生医療等製品としての実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田雅充、東京都中央区、以下「当社」）は、アラブ首長国連邦（UAE）アブダビのMasdar City Free
www.walknews.com
September 1, 2026 at 6:00 AM
cocanews.bsky.social
ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立 | ヒューマンライフコード株式会社のプレスリリース

https://www.wacoca.com/news/2921581/

世界に先駆けて臍帯由来間葉系間質細胞（以下「UC-MSCs」）を再生医療等製品としての実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田雅充、東京都中央区、以下「当社」）は、アラブ首長国連邦（UAE [...]
ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立 | ヒューマンライフコード株式会社のプレスリリース - News | wacoca.com
ヒューマンライフコード株式会社のプレスリリース（2026年9月1日 10時17分）ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立
www.wacoca.com
September 1, 2026 at 5:31 AM
maskblochtx.bsky.social
While it felt important to share this promising news, this also serves as a bittersweet reminder that our pets can contract Covid 19 just like we can. Researchers are finding that this can cause life-threatening health issues in them much like it does in us.
#covid19 #cats #mutualaid #fip
Down the left hand side of the graphic, large green and orange font reads, “Cats Illuminate A Cure For Long Covid” against a navy blue background. This larger text is flanked by smaller white text above and below it which reads respectively, “Good News!” and “Long COVID isn’t fully understood yet, but scientists are closing in on crucial clues by investigating a similar phenomenon in cats.” To the right of the bulletin, a graphic of a pink cat sits in a white cloud with a winged pink halo floating above its head. Its beady eyes peer to the upper righthand corner where a large red graphic of the novel coronavirus floats. It has fangs and an angry look on its face. The Houston mask bloc logo floats in the bottom right hand corner—a simple light blue circle with a dark blue mask and the text "Mask Bloc HTX". Against the same navy background, three centered paragraphs elaborate: White text reads, “A new study published in Stem Cells Translational Medicine explains how a relatively rare feline disease is almost like a cat version of long COVID.” Orange text reads, “Similar to severe coronavirus infections in humans, feline infectious peritonitis (FIP) sends cats’ immune system off-kilter.” Green text reads, “Therapy involving mesenchymal stromal cells, however, has shown promise in restoring immune function in cats, potentially serving as a blueprint for long COVID research.” Against the same navy background, three more centered paragraphs explain: Orange text reads, “Even if you treat the infection with antivirals, your immune system oftentimes still won't go back to normal or where it was before infection,” said corresponding author Amir Kol—a professor at the UC Davis School of Veterinary Medicine—in a statement”. White text reads, “This might have long-lasting effects on your health, and this study shows that MSC may help.” Green text reads, “Reversing immune dysfunction after viral infection may be possible because these cells are present in almost all tissues and are being used in therapeutic applications that modulate the immune system.” Against the same navy background, three final centered paragraphs summarize the experiment: Green text reads, “Researchers involved in the new study tested cellular therapy on cats with enlarged lymph nodes to assess how well their immune systems could recover.” White text reads, “In a clinical trial, one group of cats received antiviral drugs along with infusions of MSCs, while a second group received antiviral drugs and placebo infusions.” Orange text reads, “According to the researchers, cats treated with MSC therapy had fewer overly active T and B cells (which are associated with immune overdrive) and more regulatory T cells (which can calm the immune system). These cats also formed long-term ‘memory’ cells that are vital in protecting the body in the future.”
July 31, 2025 at 4:04 PM
cocanews.bsky.social
ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立 | ヒューマンライフコード株式会社のプレスリリース

https://www.wacoca.com/news/2921581/

世界に先駆けて臍帯由来間葉系間質細胞（以下「UC-MSCs」）を再生医療等製品としての実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田雅充、東京都中央区、以下「当社」）は、アラブ首長国連邦（UAE [...]
ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立 | ヒューマンライフコード株式会社のプレスリリース - News | wacoca.com
ヒューマンライフコード株式会社のプレスリリース（2026年9月1日 10時17分）ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立
www.wacoca.com
September 1, 2026 at 5:02 AM
cocanews.bsky.social
ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立 | ヒューマンライフコード株式会社のプレスリリース

https://www.wacoca.com/news/2921581/

世界に先駆けて臍帯由来間葉系間質細胞（以下「UC-MSCs」）を再生医療等製品としての実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田雅充、東京都中央区、以下「当社」）は、アラブ首長国連邦（UAE [...]
ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立 | ヒューマンライフコード株式会社のプレスリリース - News | wacoca.com
ヒューマンライフコード株式会社のプレスリリース（2026年9月1日 10時17分）ヒューマンライフコード、UAE・アブダビに中東・北アフリカ地域の事業会社「Human Life CORD MENA」を設立
www.wacoca.com
September 1, 2026 at 4:59 AM
anjiedeenyc.bsky.social
omnistem.com/legally-acce...
Where Americans Can Legally Access Expanded UC-MSCs
FDA rules block expanded UC-MSC therapy at US clinics. Here's why, plus the two legal paths Americans have: clinical trials and licensed clinics abroad.
omnistem.com
August 10, 2026 at 5:53 PM
newsen.bsky.social
Porton Advanced Marks a Major Milestone with FDA Acceptance of UC-MSCs Cell Bank for Exosome Production#United_States#exosome_therapy#Porton_Advanced#Cranbury,_NJ#UC-MSCs
Porton Advanced Marks a Major Milestone with FDA Acceptance of UC-MSCs Cell Bank for Exosome Production
Porton Advanced's new UC-MSCs Cell Bank for exosome production has received FDA acceptance, enhancing their position in the exosome therapy market.
third-news.com
July 8, 2026 at 2:10 PM
newsen.bsky.social
Porton Advanced Achieves FDA Drug Master File Acceptance for UC-MSCs Cell Bank in Exosome Production#USA#Cranbury#Porton_Advanced#UC-MSCs#Exosome_Manufacturing
Porton Advanced Achieves FDA Drug Master File Acceptance for UC-MSCs Cell Bank in Exosome Production
Porton Advanced's UC-MSCs Cell Bank has received FDA Drug Master File acceptance, crucial for accelerating exosome manufacturing regulatory processes.
third-news.com
July 8, 2026 at 1:10 PM
l2plabs.bsky.social
Porton Advanced's UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
CRANBURY, N.J. and SUZHOU, China, July 8, 2026 /PRNewswire/ -- Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has been accepted for filing by the FDA's Center for Biologics Evaluation and...
dlvr.it
July 8, 2026 at 1:03 PM
gregoryai.bsky.social
Bio 3D conduit is composed of human umbilical cord–derived mesenchymal stromal cells (UC-MSCs) using bioprinting technology. At 10 weeks postoperatively, the Bio 3D group showed better motor and sensory recovery compared with the allog..#MSchata#MSM#Neurologyg#MultipleSclerosisi#NeuroSkyk#MedSkyky
Efficacy and safety of Bio 3D conduits composed of human umbilical cord–derived mesenchymal stromal cells: A proof-of-concept study in a canine ulnar nerve defect model
Bio 3D conduit is composed of human umbilical cord–derived mesenchymal stromal cells (UC-MSCs) using bioprinting technology. At 10 weeks postoperatively, the Bio 3D group showed better motor and senso
gregory-ms.com
August 4, 2025 at 1:00 PM
cincykidsoaacd.bsky.social
Congratulations to the Hidden Gem Awardee!
Sarah Luthy, MD, MSCS
Attending Physician, Hospital Medicine
Assistant Professor, UC Department of Pediatrics
Nominated by RosaMarie Maiorella
July 28, 2025 at 12:36 PM
prtimes.jp.web.brid.gy
ヒューマンライフコード、Abu Dhabi Biobankと戦略的パートナーシップに関する基本合意を締結
[ヒューマンライフコード株式会社] 臍帯由来間葉系間質細胞（UC-MSCs）を基盤とした細胞治療の研究開発を行うバイオテクノロジー企業、ヒューマンライフコード株式会社（代表取締役社長：原田 雅充、所在地：東京都中央区、以下「当社」）は、UAEア...
prtimes.jp
March 23, 2026 at 5:26 PM
prtimes.jp.web.brid.gy
シリーズC累計19億円の資金調達を完了
[ヒューマンライフコード株式会社] 　世界に先駆けて、臍帯由来間葉系間質細胞（以下「UC-MSCs」）の再生医療等製品としての実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田 雅充、所在地：東京都中央区、以下「当社」...
prtimes.jp
November 25, 2025 at 2:51 AM
prtimes.jp.web.brid.gy
シリーズCセカンドクローズにて総額15.7億円の資金調達を実施
[ヒューマンライフコード株式会社] 　世界に先駆けて、臍帯由来の間葉系間質細胞（以下「UC-MSCs」）の再生医療等製品として実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田 雅充、所在地：東京都中央区、以下「当社」...
prtimes.jp
October 20, 2025 at 12:14 AM
prtimes.jp.web.brid.gy
シリーズCセカンドクローズにて総額15.7億円の資金調達を実施
[ヒューマンライフコード株式会社] 　世界に先駆けて、臍帯由来の間葉系間質細胞（以下「UC-MSCs」）の再生医療等製品として実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田 雅充、所在地：東京都中央区、以下「当社」...
prtimes.jp
October 19, 2025 at 6:13 PM
prtimes.jp.web.brid.gy
シリーズCセカンドクローズにて総額15.7億円の資金調達を実施
[ヒューマンライフコード株式会社] 　世界に先駆けて、臍帯由来の間葉系間質細胞（以下「UC-MSCs」）の再生医療等製品として実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田 雅充、所在地：東京都中央区、以下「当社」...
prtimes.jp
October 18, 2025 at 4:10 PM
prtimes.jp.web.brid.gy
シリーズCセカンドクローズにて総額15.7億円の資金調達を実施
[ヒューマンライフコード株式会社] 　世界に先駆けて、臍帯由来の間葉系間質細胞（以下「UC-MSCs」）の再生医療等製品として実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田 雅充、所在地：東京都中央区、以下「当社」...
prtimes.jp
October 18, 2025 at 10:09 AM
prtimes.jp.web.brid.gy
シリーズCセカンドクローズにて総額15.7億円の資金調達を実施
[ヒューマンライフコード株式会社] 　世界に先駆けて、臍帯由来の間葉系間質細胞（以下「UC-MSCs」）の再生医療等製品として実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田 雅充、所在地：東京都中央区、以下「当社」...
prtimes.jp
October 17, 2025 at 2:08 PM
prtimes.jp.web.brid.gy
総額約7.7億円の資金調達を実施
[ヒューマンライフコード株式会社] 　世界に先駆けて、臍帯由来の間葉系間質細胞（以下「UC-MSCs」）の再生医療等製品として実用化と普及を目指すヒューマンライフコード株式会社（代表取締役社長：原田 雅充、所在地：東京都中央区、以下「当社」...
prtimes.jp
October 9, 2025 at 2:44 AM
longtail-news.bsky.social
Feed: "Billion Stem Cells"
By: James W. Watson on Wednesday, May 14, 2025
Treating COVID-19 with Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs): A Promising Approach
The study was published by the team of Academician Wang Fusheng from the Fifth Medical Center of PLA General Hospital and the National Clinical Research Center for Infectious Diseases. It further verified the safety and effectiveness of mesenchymal stem cells (MSC) in treating patients recovering from COVID-19, providing new ideas for the treatment of COVID-19.
www.billionstemcells.com
May 14, 2025 at 2:45 PM
newsen.bsky.social
Human Life Code Secures Approx. 770 Million Yen in Funding for MSC Product Development#Japan#Tokyo#regenerative_medicine#Human_Life_Code#UC-MSCs
Human Life Code Secures Approx. 770 Million Yen in Funding for MSC Product Development
Human Life Code, aiming to innovate regenerative medicine, announces funding of approximately 770 million yen to bolster global operations and clinical trials.
third-news.com
October 9, 2025 at 1:52 AM
zongjinli.bsky.social
Our recent work on J Trans Med, Translational potential of GMP-grade human umbilical cord-derived mesenchymal stem cells (UC-MSCs) in traumatic spinal cord injury: a preclinical study in rat
link.springer.com/article/10.1...
July 2, 2026 at 10:18 AM